转基因：美国认错了。

2015-8-27 12:48| 发布者: 风在手| 查看: 4271| 评论: 21|原作者: 直言了|来自: 直言了博客

摘要: 转基因：美国认错了。直言了，2015-08-05 /2015-08-23 19:41:14。 http://zhiyanle.blog.hexun.com/101722816_d.html .... .... 今年07月02日，美国白宫以科技顾问备忘录形式颁布了行政令，标题挺长： MEMO ...

转基因：美国认错了。

Sec. III. Independent Assessment.

The EPA， FDA， and USDA shall commission an external， independent analysis of the future landscape of biotechnology products that will identify （1） potential new risks and frameworks for risk assessment and （2） areas in which the risks or lack of risks relating to the products of biotechnology are well understood. The review will help inform future policy making. Due to the rapid pace of change in this arena， an external analysis should be completed at least every five years.

Sec. IV. Budgeting for Efficiency.

The EPA， FDA， and USDA shall work with OSTP and OMB， within the annual President’s budget formulation process， to develop a plan for supporting the implementation of this memo in Agency FY 2017 budget requests and， as appropriate， in future budget submissions.

Sec. V. Annual Reporting.

For at least five years， starting one year after the release of the strategy described in Section II， the working group will produce an annual report on specific steps that agencies are taking to implement that strategy and any other steps that the agencies are taking to improve the transparency， coordination， predictability， and efficiency of the regulation of biotechnology products. This report will be made available to the public by the Executive Office of the President.

Sec. VI. General Provisions. Nothing in this memorandum shall be construed to impair or otherwise affect:

（a） the mission as established by law for any agency;
（b） the authority granted by law to any agency or the head thereof; or
（c） the functions of the Director of the Office of Management and Budget relating to budgetary， administrative， regulatory， or legislative proposals.

Nothing in this memorandum shall be construed to require the disclosure of confidential business information or trade secrets， classified information， law enforcement sensitive information， or other information that must be protected in the interest of national security or public safety.

This memorandum is not intended to， and does not， create any right or benefit， substantive or procedural， enforceable at law or in equity by any party against the United States， its departments， agencies， or entities， its officers， employees， or agents， or any other person.

Notes:

[1] For the purpose of this memo， “biotechnology products” refers to products developed through genetic engineering or the targeted or in vitro manipulation of genetic information of organisms， including plants， animals， and microbes. It also covers some of the products produced by such plants， animals， and microbes or their derived products as determined by existing statutes and regulations. Products such as human drugs and medical devices are not the focus of the activities described in this memo.

[2] “Improving Regulation and Regulatory Review”， Executive Order 13563， January 18， 2011.
[3] “Identifying and Reducing Regulatory Barriers”， Executive Order 13610， January 10， 2012.

[4]“Principles for Regulation and Oversight of Emerging Technologies”， Memorandum for the Heads of Departments and Agencies， March 11， 2011.

[5] http://www.aphis.usda.gov/brs/fe ... nated_framework.pdf
[6] https://www.whitehouse.gov/sites ... _reg_6753__1992.pdf

# # #



我的更多文章

1 2 3 4 56 / 6 页

鲜花

握手

雷人

路过

鸡蛋

收藏邀请

		自动登录	找回密码
密码			立即注册

转基因：美国认错了。

相关阅读

最新评论

相关分类